Back to results
US 2022/0186314 A1Published application
Methods for diagnosing and treating inflammatory bowel disease
AssigneeGenentech, Inc.
InventorsJason A. Hackney, Mary Keir, Gaik Wei Tew
Life of this patent
Estimating the term…
Abstract
Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
Claims27
A method of treating a subject having a gastrointestinal inflammatory disorder, the method comprising:
- (a) measuring the mRNA expression level of at least one gene selected from the group consisting of CCL3, VNN3, INHBA, and IL1A in a biological sample from the subject;
- (b) comparing the mRNA expression level of the at least one gene measured in (a) to a reference level for the at least gene;
- (c) identifying the subject as likely to have a response to a therapy comprising an integrin beta7 antagonist when the mRNA expression level of the at least one gene measured in (a) is below the reference mRNA expression level of the at least one gene;
- and (d) administering the therapy to the subject identified in (c).
1 more element
Dependencies are inferred from the claim text.